The multiple myeloma landscape is evolving, with bispecific T-cell engagers offering hope.
Chloe Siu, PharmD, BCPS, BCOP
Advertisement
Articles by Chloe Siu, PharmD, BCPS, BCOP
This review discusses the prevalence, mechanisms of development, and evolving treatment landscape in chronic lymphocytic leukemia.
Advertisement
Latest Updated Articles
Emerging Bispecific T-Cell Engagers in Myeloma: Promises and HurdlesPublished: April 7th 2025 | Updated:
Pirtobrutinib and BTK Inhibitors in the CLL Treatment LandscapePublished: April 17th 2024 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Reformulated Ranitidine After 5-Year Absence
2
Gluteus Maximus Muscle Shape Changes Tied to Aging, Frailty, and Type 2 Diabetes
3
Redefining the Role of GLP-1 Therapies: The Clinical Trials Behind the Expanding Indications
4
FDA Approves Sibeprenlimab for Patients with IgAN
5
